CombiGene AB (publ)

Stockholm Stock Exchange COMBI.ST

CombiGene AB (publ) Inventory for the year ending December 31, 2023

CombiGene AB (publ) Inventory is NA for the year ending December 31, 2023. Inventory is the value of goods held by a company for sale or used in the production process.

CombiGene AB (publ) Inventory for the year ending December 31, 2019 was USD 212.80 K.

Key data

Date	Inventory	Goodwill	Total Assets	Current Liabilities

Stockholm Stock Exchange: COMBI.ST

CombiGene AB (publ)

CEO	Mr. Peter Ekolind
IPO Date	May 25, 2015
Location	Sweden
Headquarters	Agavagen 52A
Employees	10
Sector	Healthcare
Industries Biotechnology

Description

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.

Key trends

Past 5 years